iTBS induces a suppression-rebound pattern in human cortical excitability

TL;DR: The most-used "excitatory" brain stimulation protocol in psychiatry — intermittent theta-burst stimulation (iTBS), FDA-cleared for depression — was put under the microscope of intracranial electrodes in 20 neurosurgical patients. The immediate effect was the opposite of the textbook story: for about a minute after iTBS, cortical reactivity in regions connected to the stimulation site was suppressed, and only over the following minutes did excitability rebound above baseline. A shift in resting-state excitation/inhibition balance tracked the rebound, and three patients receiving actual transcranial TMS-iTBS showed a compatible pattern. If this holds, a lot of contradictory human iTBS literature suddenly makes sense — different studies were probing different phases of the same dynamic.

The premise being tested

iTBS is a rhythmic stimulation pattern: triplets of pulses at 50 Hz, delivered in bursts at 5 Hz (the "theta" rhythm), on for 2 seconds and off for 8, repeated for a few minutes. Its entire clinical justification rests on a chain of inference built decades ago: theta-burst patterns induce long-term potentiation (LTP) in hippocampal slices, and early human studies found that iTBS to motor cortex boosted muscle-evoked responses. Therefore, the reasoning went, iTBS to dorsolateral prefrontal cortex (DLPFC) should potentiate that circuit, and that potentiation treats depression.

The problem is that every link in that chain is shaky outside motor cortex. The motor cortex readout (EMG) doesn't exist for prefrontal regions. TMS-EEG evoked potentials — the standard non-invasive probe of cortical reactivity — have yielded a mess of contradictory findings, with both excitation and inhibition reported after iTBS, contaminated by the click and scalp-tap sensations of the TMS pulse itself. Recent well-controlled studies have even failed to replicate the original motor-cortex excitation. And curiously, the leading clinical hypothesis for why DLPFC iTBS treats depression involves inhibiting downstream subgenual cingulate — so the field simultaneously assumes iTBS is excitatory and hopes it's inhibitory, depending on which node you ask about.

Nobody had directly measured what iTBS does to population neural activity in higher-order human cortex. That requires electrodes inside the brain.

The experiment

The authors recruited 20 patients already implanted with stereo-EEG depth electrodes for epilepsy surgery planning — the one setting where you can both stimulate and record inside a living human brain. The design is elegantly simple:

1. Deliver blocks of single-pulse electrical stimulation (27 pulses at 0.3 Hz, 7 mA) as a probe. Each pulse evokes a response — a cortico-cortical evoked potential (CCEP) — at connected recording sites. Think of it as pinging the network and measuring the echo.
2. Alternate these probe blocks with sessions of intracranial iTBS or sham (3 minutes of rest — active intracranial stimulation is imperceptible, so no masking stimulus is needed). Most subjects got 3 iTBS and 3 sham sessions.
3. Compare the pulse-evoked spectral response before vs. after each intervention. The primary readout is high-frequency activity (HFA, 75–180 Hz), a well-established proxy for population spiking and hence local excitability.

Channels were split into "in-network" (large baseline CCEPs, i.e., strongly connected to the stimulation site — 71 of 2772 channels at the strictest threshold, across 12 subjects) and "out-of-network" controls (weakest CCEPs, count-matched per subject).

What they found: suppression first

The textbook prediction is that post-iTBS evoked responses should be bigger (potentiation). The opposite happened. In in-network channels, pulse-evoked HFA was significantly reduced after iTBS, specifically in a window 700–850 ms after each probe pulse (minimum at 750 ms: intercept −0.392, Wald z = −3.29, FDR-corrected p = 0.022, via linear mixed-effects models that respect the channels-within-subjects hierarchy). Theta-band (4–8 Hz) evoked power was suppressed too; gamma and beta were not.

Three controls make this convincing rather than a fluke:

• Sham showed nothing. Pre- vs. post-sham HFA was flat (best window p = 0.86 corrected), and the active-vs-sham contrast in the key window was strong (z = −5.50, p < 0.001).
• Out-of-network channels showed nothing (best window p = 0.83 corrected), and differed significantly from in-network (p = 0.016). So this isn't a global brain-state drift — it's network-specific.
• The effect scales with connectivity. Across channels, larger baseline CCEP amplitude (stronger effective connectivity to the stimulation site) predicted greater HFA suppression (β = −0.177, p = 0.014), even after regressing out Euclidean distance to the stimulation site. That dose-response relationship in connectivity space is the kind of internal consistency you rarely get in stimulation studies.

There was also a hint of accumulation across doses: suppression was weakest after the first iTBS session and strongest after the third (session 3: HFA z = −3.07, p = 0.002; theta z = −3.95, p < 0.001), though the formal linear trend across sessions fell just short of significance (theta p = 0.057, HFA p = 0.094). The authors frame this cautiously as possible metaplasticity — the brain's response to stimulation depends on its stimulation history.

Then the rebound — hiding inside the sham condition

Here's the part I find most satisfying as a piece of scientific detective work. The sham comparisons were null on average, but the sham-period data had a persistent, puzzling upward trend in HFA. Why would doing nothing increase excitability?

Because in this alternating design, "sham" periods always occur several minutes after an iTBS session. The sham blocks weren't a clean baseline — they were sitting inside the recovery trajectory of the previous dose. When the authors laid all probe blocks out in chronological order, the picture snapped into focus: evoked HFA starts below baseline immediately post-iTBS, then climbs, crossing baseline and ending above it before the next dose.

Quantitatively: across the ~15-minute stretch between the first post-iTBS probe block and the last pre-next-iTBS block, in-network HFA rose significantly (pooled across sessions: intercept = 0.026, z = 2.45, p = 0.014; theta pooled: z = 3.41, p < 0.001). Binning trials more finely, suppression was confined to roughly the first minute after iTBS; by ~4 minutes, HFA was significantly elevated above baseline (p = 0.042) and stayed numerically elevated for the following 6–7 minutes. Out-of-network channels showed no significant rebound.

A probe-free confirmation: the aperiodic exponent

One worry: maybe the single-pulse probes themselves (a form of low-frequency repetitive stimulation) create these dynamics. So the authors turned to resting-state data with no probes at all, using the aperiodic exponent of the power spectrum — the 1/f^\chi slope, where a steeper slope (higher \chi) is associated with relatively more inhibition and a flatter slope with more excitation. This is the FOOOF-based E/I proxy from Gao/Voytek-lineage work, and here it gets a nice validation opportunity.

In-network channels showed a significant post-iTBS drop in the exponent — flatter spectra, more excitation — pooled across sessions (intercept = −0.290, z = −2.19, p = 0.028), growing with successive doses and reaching per-session significance at session 3 (p = 0.047, uncorrected). Out-of-network channels: nothing, with a significant network × iTBS interaction (z = 3.06, p = 0.002). Because the resting measurement necessarily comes after the 3-minute probe block, it lands in the rebound phase — so finding an excitatory shift there is exactly consistent with the timeline. Even better, channels showing the deepest evoked suppression showed the largest resting excitation increase (β = 0.158, p = 0.016): the two phases of the dynamic are coupled at the single-channel level.

Does it transfer to real TMS?

Direct electrical stimulation through a depth electrode is physically very different from a TMS coil: TMS engages orders of magnitude more cortex and comes with auditory/somatosensory side effects. So the authors ran 3 additional implanted patients through TMS-delivered iTBS to DLPFC, recording intracranially.

The honest summary: directionally consistent, statistically weak. In the pre-specified 0.7–0.85 s window, theta and HFA decreased numerically but not significantly (theta p = 0.14, HFA p = 0.60), with one of three subjects going the wrong way on HFA. An expanded analysis found significant HFA suppression at an earlier window (0.15–0.4 s), with the same inverse relationship between evoked-potential amplitude and suppression (HFA β = −0.653, p = 0.035). And there's a suggestive timing story: the TMS probes started 3–4 minutes post-iTBS — right at the suppression-to-rebound crossover — and the subject probed latest showed the most excitation while the subject probed earliest showed the most suppression. Suggestive, but with n = 3 this is anecdote-grade. Treat the TMS arm as a plausibility check, not a replication.

Why this matters, and what to doubt

If it holds, this reframes iTBS from a static "excitatory protocol" into a protocol that launches a biphasic trajectory: ~1 minute of network suppression, then a rebound to super-baseline excitability over ~4–10+ minutes, possibly amplifying with repeated doses. Three consequences follow. First, it offers a parsimonious explanation for the notoriously inconsistent TMS-EEG literature — studies probing at different post-iTBS latencies would land on opposite sides of the crossover and reach opposite conclusions. Second, it's a methodological alarm for anyone designing stimulation experiments: probe timing must be controlled to the minute, long probe blocks should be analyzed in temporal sub-bins, and interleaved sham periods can be silently contaminated by the previous active dose's recovery. Third, the dose-accumulation hint suggests single-session experiments may be structurally incapable of detecting iTBS excitation — resonating with the clinical observation that iTBS therapies need many sessions over days.

The timescale note is important: a minutes-long rebound is too fast to be LTP proper. The authors suggest acute activity-dependent synaptic changes that may (or may not) correlate with the longer-term plasticity that presumably drives clinical effects. The bridge from this minutes-scale dynamic to weeks-scale antidepressant response remains entirely unbuilt.

Reasons for skepticism. All subjects are epilepsy patients with implanted electrodes, often on anticonvulsants — a brain that is not a clean model of typical cortical plasticity. The headline suppression rests on 71 channels in 12 subjects (robustness checks extend to 613 channels in 15 subjects at a looser threshold, which helps). The 0.7–0.85 s analysis window was identified from the data, not pre-registered, though the network-specificity, connectivity dose-response, sham contrast, and probe-free exponent analysis substantially de-risk a pure fishing-expedition reading. The dose-accumulation and rebound-scaling trends are sub-significant. The intracranial "sham" is unblinded-by-design (imperceptible stimulation, so arguably fine) but, as the authors themselves flag, temporally entangled with recovery from active sessions. And the TMS arm — the part that actually connects to clinical practice — is 3 subjects with mixed results at the pre-specified window. This is a preprint, not yet peer-reviewed.

Where to spend your reading time: Figures 5 and 6 and their accompanying Results sections are the heart of the paper — that's where the chronological re-arrangement of the data reveals the rebound and where the ~1-minute/~4-minute timing is nailed down. Figure 7 (aperiodic exponent) is the best independent corroboration. The Discussion's paragraph on how probe timing could explain literature variability is the most practically useful few sentences for anyone running TMS-EEG or neuromodulation experiments.